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COLORECTAL CANCER SCREENING: 
AWARENESS, UTILIZATION, AND BARRIERS
Straus W1, Schaffner P1, Gold K2, Pashos C3, Mansley E1
1Merck & Co., Inc, West Point, PA, USA; 2Abt Associates Inc, 
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Cambridge, MA, USA
BACKGROUND: Screening can reduce colorectal cancer
mortality, yet screening rates remain low. Data from the
Centers for Disease Control and Prevention (CDC) for
1999 suggest that only 33.7% of US adults over 40 have
ever received a sigmoidoscopy (SIG) or colonoscopy
(COL), and 31.1% have ever received a fecal occult
blood test (FOBT). OBJECTIVE: To inform policy that
may improve screening rates, we sought to characterize
the barriers associated with low screening compliance.
METHODS: A national random sample of US adults 50
years and older was conducted via random digit dial
methods. A computer assisted telephone survey was ad-
ministered to 502 subjects. Data including utilization of
FOBT, SIG, COL and x-ray with barium enema (XBE),
as well as demographics, awareness, concerns, attitudes
and beliefs about those tests were collected. RESULTS:
Screening rates were low, with awareness and screening
rates lower for Blacks/Hispanics than for Whites. For ex-
ample, Blacks and Hispanics were less aware of screening
tests (aware of FOBT  73.3%; SIG  51.7%; COL 
70%; XBE  68.3%) than Whites (88.1%, 81.8%,
87.6% and 80.1%, respectively) (p  .05). Significantly
lower screening compliance is apparent with FOBT
screening rates of 21.7% (Blacks/Hispanics) compared
with 34.8% (Whites). Other significant barriers to
screening found were: discomfort with exam; low health
care seeking behavior; low belief in value of prevention;
and low perceived personal health threat (all p  .05).
CONCLUSIONS: Lack of awareness about screening
still exists, especially among Blacks and Hispanics. Barri-
ers to screening have been observed and can potentially
be addressed by outreach and education programs.
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COLORECTAL CANCER SCREENING TESTS: 
VARIATION IN PREFERENCES BASED ON 
GENDER AND RACE
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Knowledge
of Test Ever Had Test
Compliant with
Standards
FOBT 86.7% 70.3% 33.5%
SIG 78.1% 52.0% 29.7%
COL 85.1% 40.7% 31.1%
XBE 78.1% 38.5% 17.5%
BACKGROUND: There exists a larger number of screen-
ing procedures for colorectal cancer than for any other
type of cancer. Unfortunately, screening rates remain
low. Data from the Centers for Disease Control and Pre-
vention (CDC) for 1999 suggest that only 33.7% of US
adults over 40 have ever received a sigmoidoscopy (SIG)
or colonoscopy (COL), and only 31.1% have ever re-
ceived a fecal occult blood test (FOBT). OBJECTIVE: To
better understand the types of barriers associated with
each screening method (stool-based, scope-based, x-ray/
enema-based) in order to develop patient-based prefer-
ence profiles that could be used to increase compliance
with one of the recommended screening regimens. METH-
ODS: A national random sample of US adults 50 years
and older was conducted via random digit dial methods.
A computer assisted telephone survey was administered
to 502 subjects. Data including utilization of FOBT, SIG,
COL and x-ray with barium enema (XBE), demographics,
concerns, attitudes and beliefs were collected. RESULTS:
There were significant gender differences in screening
rates based on procedure. Overall, 26.2% of women were
in compliance with SIG recommendations compared to
38.6% of men (p  .01). White respondents appeared to
be the source of this difference. Black/Hispanic men and
women had similar SIG screening rates. Conversely, there
was a significant difference in stool-based screening com-
pliance between Black/Hispanic men (40.0%) and women
(15.6%) with no gender difference among Whites. The
importance of some potential barriers differed signifi-
cantly with exam type (p  .05), with respondents being
less bothered by, and associating less discomfort with,
the FOBT. CONCLUSIONS: Preferences and perceptions
with respect to screening procedures varied by patient
characteristics. The impact of screening barriers varied by
procedure. Understanding these variations may help in
education and information dissemination and may also
assist in directing patients to more compatible screening
regimens. This might increase screening rates for this
largely preventable disease.
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COST MINIMIZATION ANALYSIS OF CEFEPIME 
VERSUS IMIPENEM-CILASTATINE IN CANCER 
PATIENTS WITH SHORT-DURATION
FEBRILE NEUTROPENIA
Vorobjov P, Fisenko V, Gerasimov V, Avxentieva M, Moscow 
Medical Academy, Moscow, Russia
OBJECTIVE: To perform pharmacoeconomical compar-
ison of cefepime versus imipenem-cilastatine used for em-
piric therapy in cancer patients with short-duration fe-
brile neutropenia in Russia. METHODS: The decision
tree was designed to analyse the costs and outcomes of
studied treatment. Probabilities of clinical success, ad-
verse events, switching to a new drug and adding extra
antibiotics were extracted from a published multicentral
randomised clinical trial. Firstly the study was planned to
be a cost-effectiveness analysis, but data obtained from
the trial, demonstrated equal efficacy of both drugs. So fi-
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nally the study was performed as cost-minimization anal-
ysis. The following costs were taken into account: the
drug acquisition price, drug preparation and administra-
tion, medications to treat failures and adverse events, in-
cluding antibiotics added to main medication. Schemes of
treatment for adverse events and choice of antibiotics for
treating clinical failures typical for clinical practice in this
country were obtained from expert panel. Costs of drugs
were derived from official price-lists of pharmacies. Hos-
pital costs were excluded, as there was no difference in
the length of treatment between the groups according to
the results of the trial. RESULTS: According to clinical
trial the probability of clinical success for short-duration
febrile neutropenia treatment in cancer patients is equal
in both drugs (79 % for cefepime and 72% for imi-
penem, equivalence, p  0.0001). Cost of treatment of 1
patient with imipenem-cilastatine including added antibi-
otics, drugs for treating failures and adverse events was
21 207,2 roubles (757,4 USD), for cefepime—10 512, 32
roubles (375,44 USD). CONCLUSION: Cefepime mono-
therapy being clinically as effective as imipenem-cilasta-
tine is twice less costly for the empirical treatment of fe-
ver in short-duration neutropenia. Changing of widely
recommended for empiric therapy of febrile neutropenia
imipenem-cilastatine for cefepime will save 10 694,88
roubles (382 USD) in each treated patient.
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HEALTH-RELATED QUALITY OF LIFE AFTER 
ANDROGEN DEPRIVATION THERAPY IN MEN 
WITH PROSTATE CANCER
Lubeck DP, Grossfeld GD, Carroll PR
University of California, San Francisco, San Francisco, CA, USA
INTRODUCTION and OBJECTIVES: Treatment for
prostate cancer has significant impact on health-related
quality of life (HRQOL). We examine HRQOL in a co-
hort of men who opted for surveillance as initial treat-
ment followed by androgen deprivation therapy (ADT)
and compare them with other treatments. METHODS:
CaPSURE (Cancer of the Prostate Strategic Urologic Re-
search Endeavor) is a national observational database of
men with prostate cancer. We identified a cohort of
newly diagnosed men with prostate cancer who com-
pleted two or more instruments that measure generic and
disease-specific HRQOL. Individuals were grouped by
initial treatment: ADT, surveillance, radical prostatec-
tomy, and radiation therapy. RESULTS: Initial treatment
was as follows: ADT (n  167), surveillance (n  106),
radical prostatectomy (n  351), radiation therapy (n 
75). Sixty-seven men selected surveillance followed by
ADT. Mean age at diagnosis was 73 years with surveil-
lance patients being older. Men had significantly poorer
urinary (decline of 7 points on a 100 point scale) and sex-
ual function (decrease of 10 points) compared with sur-
veillance. HRQOL for ADT, surveillance and radiation
therapy patients changed little over the year following
treatment, while men undergoing radical prostatectomy
showed improvement in all aspects of HRQOL. Scales
are scored from 0–100 with 100  better function and a
difference of 7–10 points is considered clinically signifi-
cant. CONCLUSIONS: Patients receiving ADT had re-
duced energy, poorer sexual and urinary function and
were more bothered by their urine function than patients
undergoing other treatments. Longer follow-up after
start of ADT and surveillance is needed to discern the im-
pact of other factors, including comorbidities.
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TREATMENT OF METASTATIC BREAST CANCER
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OBJECTIVE: To compare paclitaxel (pac) and docetaxel
(doc) in the treatment of second line or greater metastatic
breast cancer using a cost-effectiveness analysis. METH-
ODS: Costs were collected prospectively from 31 patients
in a single outpatient center. Direct medical costs were
collected (e.g., all medications, physician/clinic/labora-
tory visits, ER, hospitalizations, home health care, con-
sultations, special procedures, transfusions, phone calls,
and miscellaneous) and costs were defined using Medi-
care reimbursement rates and AWP for drugs. Effective-
ness measures were obtained from two phase III trials
conducted by Nabholtz. Sensitivity analyses are currently
underway. RESULTS: The average cost per cycle of che-
motherapy was $4,298 and $2,869 for doc and pac re-
spectively. The objective response rates (OR) obtained
for doc and pac in the phase III trials were 30% and 26%
respectively. The cost-effectiveness (CE) ratio for doc is
$14,327 per one-percent increase in OR. The CE ratio
for pac is $11,035 per one-percent increase in OR. An in-
cremental CE analysis suggests that using doc costs
$35,725 per one-percent increase in OR compared to
pac. CONCLUSIONS: The cost-effectiveness ratios sug-
gest that pac is the more cost-effective choice. The incre-
mental cost-effectiveness analysis still supports the use of
pac; however, doc is not out of the standard range of
payment for gains in effectiveness. Physicians and third
party payers should use this information along with cost-
utility studies to help guide decisions on treatment for
metastatic breast cancer patients.
